EGT's breeding could not be better. It is from the stable of Cathal Friel, the entrepreneur who helped build and sell Amryt Pharma for just shy of $1.5 billion.
Raglan Capital, the private investment vehicle behind Amryt, hVivo and Poolbeg Pharma, is preparing to bring yet another of its small-cap companies to the stock
Pharmaceutical services firm Hvivo, formerly Open Orphan, will pay a dividend to shareholders after a “record financial and operational performance” last year.